Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Jan 7, 2022; 10(1): 155-165
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.155
Table 1 Demographic and clinical characteristics of patients who had abnormal hypermetabolism in the thyroid (n = 339)
Characteristics
Male
Female
Total
Subjects (n)185154339
Age (yr, mean ± SD)68 ± 11.263 ± 15.066 ± 13.3
Primary malignancy (n)
Lung643397 (28.6%)
Colorectal311142 (12.4%)
Breast05050 (14.7%)
Lymphoma151530 (8.8%)
Gastrointestinal20828 (8.3%)
Hepatobiliary20828 (8.3%)
Head and neck13215 (4.4%)
Other222749 (14.5%)
Table 2 Classification of 46 focal hypermetabolic thyroid lesions as malignant or benign according to the type of primary cancer (n = 46)
Primary cancer
Malignant
Benign
Total
Breast5611
Kidney101
Colorectal235
GIST011
Lung8816
Stomach202
Uterine cervix303
Sarcoma101
Urinary bladder101
Salivary gland101
Lymphoma123
Bone101
Total262046
Table 3 Examples of F-18 fluorodeoxyglucose positron emission tomography-computed tomography parameters
Parameters
Malignant (n = 26)
Benign (n = 20)
P value
SUVmax10.8 ± 7.56.5 ± 3.00.012
SUVpeak6.8 ± 5.74.4 ± 2.00.058
MTV25.06 ± 5.26.7 ± 6.60.354
SUVmean23.8 ± 1.53.0 ± 0.50.011
TLG225.5 ± 48.921.3 ± 24.00.735
MTV2.53.5 ± 4.53.7 ± 4.20.872
SUVmean2.54.5 ± 1.63.6 ± 0.70.014
TLG2.522.0 ± 47.614.8 ± 19.00.532